Chemotherapy plus durvalumab in triple negative breast cancer from statistical significant results Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Loibl speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from Gepar Nuevo, a trial of anthracycline chemotherapy with durvalumab as a treatment for patients with triple negative breast cancer.nnShe outlines the patient cohort and stratification for the trial, and the pCR findings which fell just short of statistical significance, though ORR rates were statistically significant, with the best outcomes from patients who were 'primed' with d
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)